ProsTIC key research

Latest Published Research

• The FACT-RNT: A new standardized tool to monitor relevant symptoms and toxicities among Prostate Cancer patients in RNT trials and real-world settings.

• The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. 

• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2022. 

• Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Selected Top 10 Research papers with Impact

1. Hofman MS, Louise E, Shahneen Sandhu, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 February 11.
   Practice changing first RCT of 177Lu-PSMA-617, a novel treatment for men with metastatic prostate cancer. First author and study chair. Oral presentations at ASCO Annual and ASCO GU: 2020, 2021, 2022 
2. Hofman MS, Nathan L, Roslyn JF, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet Oncol., 2020 March 22
   Landmark 10-site RCT establishing PSMA PET/CT as a new standard-of-care in comparison to CT/bone scanning. Presented as EAU20 plenary. FDA approval of 68Ga-PSMA-11 2020. Cited in 2021 NCCN guidelines 
3. Jeremie C, Francesco C, Matthias E, et al. 18F-fluciclovine PET-CT vs 68Ga-PSMA-11 PET-CT: a prospective, single-centre, single-arm, comparative imaging trial. Lancet oncol. 2019 September 09. (CI Hofman) Practice changing study, contributed to FDA approval 2020 
4. Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022 Apr 
5. Hofman MS, John V, Rodney JH, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet oncol. 2018 June 1 (CI Hofman, Murphy). First-in-field publication. Led to Endocyte/AAA / Novartis $2b acquisition, multiple ph2/3 studies. 
6. Hofman MS, Rodney JH, Tobias M, et al. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiograph., 2018. Highly cited Radiographics manuscript based on award winning RSNA presentation 
7.  Marlon P, Nathan P, Matthew R, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urol., 2016 April 01. Widely cited meta-analysis. 2020 update also published with >350 citations 
8. Emmett LM, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy DG, Stricker P, Hope TA, Hofman M. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med. 2022 Mar  
9. Emmett L, Buteau J, et al. The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021 Aug 28. Awarded EAU Scientific Manuscript of the Year 2021 
10. Buteau JP, Martin AJ, Emmett L, et al. TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Nov 23. 

Other Original Research

1.  Inderjeeth AJ, Iravani A, Subramaniam S, Conduit C and Sandhu S. Novel radionuclide therapy combinations in prostate cancer. Therapeutic Advances in Medical Oncology, 2023 Aug 2. 
2. Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023 Jul;84(1):36-48.
3. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 Jul;64(7):1024-1029.
4. Kelly BD, Ptasznik G, Roberts MJ, Doan P, Stricker P, Thompson J, Buteau J, Chen K, Alghazo O, O'Brien JS, Hofman MS, Frydenberg M, Lawrentschuk N, Lundon D, Murphy DG, Emmett L, Moon D. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. Eur Urol Open Sci. 2023 Jun 2;53:90-97.
5.  Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, Kessel K, Schäfers M, Yu J, Haug AR, Hacker M, Bögemann M, Bodei L, Morris MJ, Hofman MS, Rahbar K. A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology. 2023 May;307(4):e222010
6. Roberts MJ, Hruby G, Kneebone A, Martin JM, Williams SG, Frydenberg M, Murphy DG, Namdarian B, Yaxley JW, Hofman MS, Davis ID, Emmett L. Treatment de- intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU Int. 2023 May 22.
7. Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. BJU Int. 2023 May;131(5):588-595.
8. Chan TH, Haworth A, Wang A, Osanlouy M, Williams S, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Reynolds HM. Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy. EJNMMI Res. 2023 Apr 26;13(1):34.
9. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman MS, Siva S. Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer. Front Oncol. 2023 Mar 13;13:1134884.
10. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman MS, Siva S. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2023 Feb 27;40:100608..
11. Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Jul 1.
12. Gudenkauf LM, Chavez M, Maconi ML, et al. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12.
13. Viljoen B, Hofman MS, Chambers SK, Dunn J, Dhillon HM, Davis ID, Ralph N. Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study. PLoS One. 2022 Nov 9;17(11):e0276063.
14.  Beyer T, Czernin J, Freudenberg L, et al.. A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med. 2023 Jan 6.
15. Conduit C, Koh TT, Hofman MS, Toner GC, Goad J, Lawrentschuk N, Tai KH, Lewin JH, Tran B. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging. 2022 Oct 8;22(1):58.
16. Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. Cancers (Basel). 2022 May 31;14(11):2717. 
17. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hanna GG, Hofman MS, Siva S. Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. Front Oncol. 2022 Apr 12. 
18. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman MS, Siva S. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2022 May 17;35:84-89. 
19. Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. J Nucl Med. 2022 Apr;63(4):560-566.  
20. Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman MS, Buteau J, Murphy DG, Emmett L, Moon D. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int. 2022 Apr 1.  
21. Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med. 2022 Mar;52(2):243-254.  
22. Emmett L, Buteau J, Papa N, et al. The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021 Aug 28:S0302-2838(21)01946-1.  
23. Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 Jul 8  
24. Viljoen B, Hofman MS, Chambers SK, et al. Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: patient experiences. BMJ Support Palliat Care. 2021 Aug 9:bmjspcare-2021-002994. doi: 10.1136/bmjspcare-2021-002994.  
25. Hofman MS, Emmett L, Sandhu S, et al.; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 27;397(10276):797-804.  
26. Emmett L, Subramaniam S, Joshua A, et al.; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and the ENZA-p investigators. ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021 May 24.  
27. Gafita A, Wang H, Robertson A, et al. Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2021 May 28  
28. Dhiantravan N, Emmett L, Joshua AM, et al. UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer. BJU Int. 2021 Mar 7.  
29. Le Pennec R, Iravani A, Woon B, et al. Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. Front Med 2021 Feb 16  
30. McIntosh L, Jackson P, Hardcastle N, et al. Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. EJNMMI Phys. 2021 Mar 7;8(1):23.  
31. Subramaniam S, Callahan J, Bressel M, et al. The role of 18F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study. J Surg Oncol. 2021 Mar;123(4):1081-1087  
32. Osman MM, Iravani A, Hofman MS, Hicks RJ. Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging. 2021 Apr 16;21(1):35.  
33. de Feria Cardet RE, Hofman MS, Segard T, et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. Eur Urol. 2021 Mar;79(3):413-418.  
34. Kalff V, Iravani A, Ackhurst T, et al. Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Intern Med J. 2021 Oct;51(10):1657-1664.  
35. Dhiantravan N, Violet J, Eapen R, et al. Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2020 Nov 7  
36. Sim IW, Borromeo GL, Tsao C, et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020 Sep 10;38(26):2971-2980.  
37. Gafita A, Fendler WP, Hui W, et al. Efficacy and Safety of 177Lu-labeled Prostate- specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020 Jun 9  
38. Anton A, Kamel Hasan O, Ballok Z, et al. Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer. BJU Int. 2020 Jun 24.  
39. Fettke H, Kwan EM, Docanto M, et al. Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer. Eur Urol 2020;78(2):173-180  
40. M Perera, N Papa, M Williams, et al. 68Ga-PSMA PET in advanced prostate cancer - updated diagnostic utility, sensitivity and specificity and distribution of PSMA-avid lesions: A systematic review and meta-analysis. Eur Urol 2020;77(4):403-17. Our previous systematic review of PSMA PET/CT published in Eur Urol in 2016 has attracted >650 citations within four years. This is our updated 2020 review which has already 160 citations.  
41. Armstrong AJ, Szmulewitz RZ, Petrylak D, et al.: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2019; 37(32):2974-2986   
42. Correa RJM, Louie AV, Siva S, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Nov;5(6):958-969  
43. S Siva, M Bressel, DG Murphy, et al. Single Fraction Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol 2018;74(4):455-462. This was a prospective study of stereotactic radiotherapy in men with oligometastatic prostate cancer as determined by PET imaging; a relevant contribution to the literature on oligometastatic disease.  
44. Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018 Mar 1;124(5):934-942.  
45. RA Taylor, M Fraser, J Livingstone, et al. Germline BRCA2 Mutations Drive Prostate Cancers with Distinct Evolutionary Trajectories. Nature Communications 2017;8:13671. Detailed PDX project describing genomic instability in localised prostate cancers from BRCA2 patients. 
46. Wyatt AW*, Azad AA*, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016 1;2(12):1598-1606  
47. Azad AA*, Volik SV*, Wyatt AW*, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015;21(10):2315-24   
48. Kwan EM, Spain L, Anton A, et al. Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial. Eur Urol (in press). Clinical Trial Protocols 
49. Dhiantravan N, Violet J, Eapen R, Alghazo O, Scalzo M, Jackson P, Keam SP, Mitchell C, Neeson PJ, Sandhu S, Williams SG, Moon D, Lawrentschuk N, Azad A, Hofman MS, Murphy DG. Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2021 Mar;7(2):234-237.  
50. Dhiantravan N, Emmett L, Joshua AM, Pattison DA, Francis RJ, Williams S, Sandhu S, Davis ID, Vela I, Neha N, Bressel M, Murphy DG, Hofman MS, Azad AA. UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021 Sep;128(3):331-342.  
51. Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int. 2020 Jan 19. doi: 10.1111/bju.14999.  
52. Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S,Azad A, Martin A, McJannett M; ANZUP TheraP team, Davis ID. TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019 Nov;124 Suppl 1:5-13.  
53. Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018 May 3.  

Review Articles and Clinical Guidelines

1. Sutherland DEK, Azad AA, Murphy DG, Eapen RS, Kostos L, Hofman MS. Role of FDG PET/CT in Management of Patients with Prostate Cancer. Semin Nucl Med. 2023 Jul 1.
2. Kostos L, Buteau JP, Hofman MS, Azad AA. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023 Jun 6.
3. Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023 Jul 9.
4. Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, Yamoah K, Ost P. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2023 Jun6.
5. Lee ST, Emmett LM, Pattison DA, Hofman MS, Bailey DL, Latter MJ, Francis RJ, Scott AM. The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. J Nucl Med. 2022 Jun;63(6):819-822.
6. Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023 Mar 17
7. Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next Generation Radiotheranostics Promoting Precision Medicine. Ann Oncol. 2023 Mar 14.
8. Gillessen S, Bossi A, Davis ID, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 Mar 3
9. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, Fendler WP. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023 Jan 20.
10. Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, Fanti S, Hofman MS. [68 Ga]Ga-PSMA Versus [18 F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol. 2022 Mar 30:S2588-9311(22)00035-9. 
    Winner European Urology Oncology #SoMe award (most influential article according to PlumX Metrics  
11. Parihar AS, Hofman MS, Iravani A. 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 Feb 2.
12. Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022 Apr 17.
    ASCO 2022 Educational Feature Presentation
13. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022 Jan;63(1):59-68.
14. Sandhu S, Guo C, Hofman MS. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021 Aug 12:jnumed.120.243295.  
15. Farolfi A, Hadaschik B, Hamdy FC, et al. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021 Oct;4(5):714-730.  
16. Ploussard G, Fossati N, Wiegel T, et al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021 Apr;4(2):150-169.  
17. Lawhn-Heath C, Salavati A, Behr SC, et al. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 May;299(2):248-260.  
18. Bagguley D, Ong S, Buteau JP, et al. The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021 Mar 16.  
19. Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA- PET. Eur J Nucl Med Mol Imaging. 2021 Feb 19.  
20. Ploussard G, Fossati N, Wiegel T, et al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021, Feb 8  
21. Farolfi A, Hadaschik B, Hamdy FC, et al. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021 Mar 6  
22. Miyahira AK, Pienta KJ, Babich JW, et al. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 Aug 31.  
23. Ravi Kumar AS, Lawrentschuk N, Hofman MS. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer. Curr Opin Urol. 2020 Sep;30(5):628-634. 
24. Mayor N, Sathianathen NJ, Buteau J, et al. PSMA Theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020 Jun 19.  
25. Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 Apr;77(4):508-547.  
26. Siva S, Udovicich C, Tran B, et al. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat Rev Urol. 2020 Feb;17(2):107-118.  
27. Iravani A, Violet J, Azad A, Hofman MS. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2019 Oct 8. doi: 10.1038/s41391-019-0174-x. [Epub ahead of print]  
28. Koschel S, Murphy DG, Hofman MS, Wong LM. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Curr Opin Urol. 2019 Nov;29(6):569-577.  
29. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019 Sep 20;11:1758835919876828.  
30. Hofman MS, Iravani A, Nzenza T, Murphy DG. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016.  
31. Ferdinandus J, Violet J, Sandhu S, Hofman MS. Prostate-specific membrane antigen theranostics: therapy with lutetium-177. Curr Opin Urol. 2018 Mar;28(2):197-204.  
32. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018 Jan-Feb;38(1):200-217  
33. Eiber M, Fendler WP, Rowe SP, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S.  
34. Hofman MS, Iravani A. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clin. 2017 Apr;12(2):219-234. doi: 10.1016/j.cpet.2016.12.004. Epub 2017 Feb 1.  
35. Udovicich C, Perera M, Siva S, et al. 68Ga-PSMA PET/CT in Advanced Prostate Cancer: current state and future trends, Prostate International 2017. Dec;5(4):125-129. 

Editorials and Commentaries

1. Ayati N, Herrmann K, Fanti S, Murphy DG, Hofman MS. More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. Eur Urol. 2023 Jan 1.
2.  Pomykala KL, Herrmann K, Padhani AR, Hofman MS, Lalumera E, Fanti S. Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers. J Nucl Med. 2022 Oct 10.
3. Murphy D, Herrmann K, Hofman M, Leading in Urology and Pioneering in Social Media Outreach: A Conversation Among Declan Murphy, Ken Herrmann, and Michael Hofman, J Nuc Med, 2022 12.
4. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022 Jun 10. 
5. Brien JS, McVey A, Kelly BD, Jenjitranant P, Buteau J, Hofman MS, Kasivisvanithan V, Eapen R, Moon D, Murphy DG, Lawrentschuk N. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU Int. 2022 May 16.
6. Hofman MS. Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. J Nucl Med. 2021 Aug 12. 
7. Hofman MS, Sandhu S, Francis RJ, Davis ID, Emmett L. Targeted radioactive therapy for prostate cancer - Authors' reply. Lancet. 2021 Aug 7. 
8. Hofman MS, Calais J, Czernin J. Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais. J Nucl Med. 2021 Aug 1;62(8):1027-1030.  
9. Hofman M. PSMA PET/CT for staging and treatment of prostate cancer. Clin Adv Hematol Oncol. 2019 Jul;17(7):370-373.  
10. Hofman MS, Emmett L. Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength? Eur Urol. 2019 Jul 24.  
11. Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N. Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. 2019 May 24.  
12. Rahbar K, Hofman MS, Schrader AJ, Boegemann M. A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naïve vs Post-Taxane metastasized Prostate Cancer Patients? J Nucl Med. 2019 Mar 29.  
13. Murphy DG, Sathianathen N, Hofman MS, Azad A, Lawrentschuk N. Where to Next for Theranostics in Prostate Cancer? Eur Urol Oncol. 2019 Mar;2(2):163-165.  
14. Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019 Apr 1;37(10):765-769.  
15. Murphy DG, Azad AA, Sandhu S, Violet J, Hofman MS. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. Eur Urol. 2019 Jun;75(6):927-928.  
16. Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World J Urol. 2018 Oct 29.  
17. Hofman MS, Violet J, Hicks RJ, Sandhu S. [(177)Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply. Lancet Oncol. 2018 Aug;19(8):e373.  
18. Hofman MS. Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT? J Nucl Med. 2017 Jun 21.  
19. Maurer T, Murphy DG, Hofman MS, Eiber M. PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet? Theranostics. 2017 May 15;7(7):2046-2047.  
20. Violet J, Hofman MS, Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer, BJUI 2017 Apr 5  
21. Murphy DG, Hofman M, Lawrentschuk N, Maurer T. Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer. BJU Int. 2017 Feb;119(2):194-195.